Combivent Respimat is owned by Boehringer Ingelheim.
Combivent Respimat contains Albuterol Sulfate; Ipratropium Bromide.
Combivent Respimat has a total of 6 drug patents out of which 0 drug patents have expired.
Combivent Respimat was authorised for market use on 07 October, 2011.
Combivent Respimat is available in spray, metered;inhalation dosage forms.
The generics of Combivent Respimat are possible to be released after 16 October, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7284474||BOEHRINGER INGELHEIM||Piston-pumping system having o-ring seal properties|| |
(1 year, 6 months from now)
|US7896264||BOEHRINGER INGELHEIM||Microstructured high pressure nozzle with built-in filter function|| |
(2 years from now)
|US7396341||BOEHRINGER INGELHEIM||Blocking device for a locking stressing mechanism having a spring-actuated output drive device|| |
(3 years from now)
|US9027967||BOEHRINGER INGELHEIM||Device for clamping a fluidic component|| |
(4 years from now)
|US7837235||BOEHRINGER INGELHEIM||Device for clamping a fluidic component|| |
(5 years from now)
|US8733341||BOEHRINGER INGELHEIM||Atomizer and method of atomizing fluid with a nozzle rinsing mechanism|| |
(7 years from now)
Market Authorisation Date: 07 October, 2011
Dosage: SPRAY, METERED;INHALATION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic